A clinical study involving individuals with inflammatory bowel disease (IBD) demonstrated nonclassical NF-κB activation with reduced responses to infliximab and adalimumab therapy, accompanied by increased expression of cIAP1/2 and various related enzymes (50). The gene discussed is NFKB1; the disease is inflammatory bowel disease.